Stada bolsters its dietary supplement portfolio with first acquisition under new majority ownershipExecutive summary: Stada announced the acquisition of Orifarm’s dietary supplement business, its first deal under the new majority owner. The deal expands Stada’s consumer‑health portfolio and enables Orifarm to focus on prescription generics, potentially altering competitive dynamics in the European OTC market. Stada (German pharmaceutical company), Orifarm (Danish generic drug maker), and the undisclosed new majority owner of Stada. Integration of the supplement brands into Stada’s operations, possible further consumer‑health M&A, and Orifarm’s increased focus on core generics R&D.Stada’s purchase of Orifarm’s supplement business marks its inaugural deal under the new majority owner, signaling a strategic push into the consumer‑health segment. The transaction lets Orifarm shed a non‑core line and concentrate on higher‑margin prescription generics, while Stada gains scale in the fast‑growing European OTC market. Though financial details are undisclosed, the move aligns with a broader industry pattern of pharma companies reshaping portfolios through targeted M&A in consumer health.Open the full case file on Beyond →
Social Pulse
AI estimate · not scraped